To include your compound in the COVID-19 Resource Center, submit it here.

Ablynx gains on Phase II RA data

Ablynx N.V. (Euronext:ABLX) gained EUR 0.94 (18%) to EUR 5.78 on Thursday after reporting interim Phase II data of IV

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE